|Positive FC detected in||HeLa cells|
|Sample-dependent, check data in validation data gallery|
CL594-60035 targets ATF4 in WB, FC (Intra) applications and shows reactivity with human samples.
|Host / Isotype||Mouse / IgG1|
|Immunogen||ATF4 fusion protein Ag1279|
|Full Name||activating transcription factor 4 (tax-responsive enhancer element B67)|
|Calculated molecular weight||39 kDa|
|GenBank accession number||BC022088|
|Gene ID (NCBI)||468|
|Conjugate||CoraLite®594 Fluorescent Dye|
|Excitation/Emission maxima wavelengths||588 nm / 604 nm|
|Purification Method||Protein G purification|
|Storage Buffer||PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.|
|Storage Conditions||Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
ATF4 is a transcription factor, that accumulates predominantly in osteoblasts, where it regulates terminal osteoblast differentiation and bone formation. As a basic leucine-zipper (bZip) transcription factor, ATF4 can regulate amino acid metabolism, cellular redox state, and anti-stress responses. It also regulates age-related and diet-induced obesity and glucose homeostasis in mammals, and has conserved metabolic functions in flies. Due to its location at chromosome 22q13, a region linked to schizophrenia, ATF4 is considered as a positional candidate gene for schizophrenia. Otherwise, since ATF4 is induced by tumour microenvironmental factors, and regulates processes relevant to cancer progression, it might serve as a potential therapeutic target in cancer. This antibody is a mouse monoclonal antibody raised against full length human ATF4 antigen. This anitbody is conjugated with CL594, Ex/Em 593 nm/614 nm.